Natalie Grinshtein

Company: Seagen

Job title: Director - Cancer Target Discovery

Seminars:

Utilizing Hindsight Following Progression of ADCs Into the Clinic 9:00 am

Target selection process and reasons behind the choice of pursuing various clinical targets Integrin β6 – an example of Seagen’s new and promising target showing early clinical success Considering reverse translation in the target selection process – lessons learned from the clinicRead more

day: Conference Day One